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บทคดัยอ่  
วตัถปุระสงค:์ เพื่อเปรยีบเทยีบการยดึตดิในการใชย้าของผูป้่วยจติเภทระหว่าง
กลุ่มเข้าร่วมโปรแกรมการศึกษาโดยใช้ภาพตัวแทนความเจ็บป่วย (Illness 
Representation Based Education Program; IRBEP) และกลุ่มทีไ่ม่ไดร้บั และ
เพือ่เปรยีบเทยีบการยดึตดิในการใชย้าระหวา่งก่อนและหลงัการเขา้รว่มโปรแกรม 
วิธีการศึกษา: การศกึษาน้ีใชร้ปูแบบการวจิยัเชงิกึง่ทดลอง (quasi-experimental 
design) โปรแกรม IRBEP สรา้งขึน้ตามแนวทางการใหก้ารศกึษาแก่ผูป้่วยโดยใช้
ภาพตวัแทนความเจบ็ป่วย(representational approach to patient education) 
เป็นแนวทางซึง่พฒันาจากแนวคดิของ Common Sense Model และ Conceptual 
Change Model ผูป้่วยจติเภท 40 รายถูกจดัเขา้กลุ่มทดลองและกลุ่มควบคุม
จํานวนเท่า ๆกนั โดยวธิกีารสุ่มประยุกต์ปจัจยัแปรปรวน (covariates adaptive 
randomization) ปจัจยัแปรปรวนทีค่วบคุมคอื การสนับสนุนของครอบครวัและ
ความถีข่องการใหย้า ประเมนิการยดึตดิในการใชย้าดว้ยแบบสอบถามพฤตกิรรม
การยดึตดิในการใชย้า (Behavior of Medication Adherence Questionnaire; 
BMAQ) ผลการศึกษา: ผูป้่วยในกลุ่มทดลองมกีารยดึตดิในการใชย้าสงูกว่ากลุ่ม
ควบคุมอยา่งมนีัยสาํคญั (t = 6.53, P < 0.01) ผูป้่วยในกลุ่มทดลองหลงัเขา้
โปรแกรม IRBEP มกีารยดึติดในการใช้ยาสูงกว่าก่อนเขา้โปรแกรมอย่างมี
นัยสาํคญั (t = -6.09, P < 0.01) สรปุ: ผลการศกึษาแสดงถงึประสทิธผิลของ
โปรแกรม IRBEP ในการเพิม่การยดึตดิในการใชย้าของผูป้ว่ยจติเภท  
 คาํสาํคญั: การยดึตดิในการใช้ยา, การใหศ้กึษาแก่ผูป้่วยโดยใชภ้าพตวัแทน
ความเจบ็ปว่ย, จติเภท, อนิโดนีเซยี  
 
 
Abstract 
Objective: To compare medication adherence of patients with 
schizophrenia between the patients who attended the Illness 
Representation Based Education Program (IRBEP) and the patients who 
did not, and to compare medication adherence before and after the IRBEP. 
Method: This study employed a quasi-experimental research design. The 
IRBEP was developed based on the Common Sense Model and 
Conceptual Change Model, a representational approach to patient 
education. Forty patients with schizophrenia were assigned into an 
experiment or control group equally by using covariates adaptive 
randomization. The controlled covariates were family support and dosage 
frequency. The Behavior of Medication Adherence Questionnaire (BMAQ) 
was used to capture medication adherence. Results: The patients in the 
experiment group had significantly higher medication adherence than those 
in control group (t = 6.53, P < 0.01). Experiment group had significantly 
higher medication adherence after attending the IRBEP than that at 
baseline (t = -6.09, P < 0.01). Conclusion: The findings showed that the 
IRBEP was effective in enhancing medication adherence among patients 
with schizophrenia.  
 Keywords: medication adherence, a representational approach to patient 
education, schizophrenia, Indonesia  
 
Introduction
Schizophrenia is a chronic mental illness which impacts 
a large number of individuals.1 The pharmacological 
approach is a main treatment for schizophrenia. 
Antipsychotic medication can help patients from experiencing 
a relapse,2 reduce re-hospitalization,3 reduce symptoms, and 
improve functioning,4 and quality of life.5 Although medication 
provides benefit for patients, suboptimal adherence to 
prescribed medication has been documented. The reasons 
that patients do not adhere to their medication include 
believing that their illness is cured while the symptoms are 
relieved, believing that medication does not work while the 
symptoms persist, or experiencing uncomfortable side effects 
from the medication.6  
Researchers have sought of interventions to enhance 
medication adherence in patients with schizophrenia. 
However, not all interventions have been proved to offer an 
effective enhancement. Moreover, results were inconsistent. 
A pilot study in five patients with schizophrenia was 
conducted by Staring, Mulder, and Priebe.7 The researchers 
provided incentive to each patient for each time they took 
depot injection of medication. The study was conducted for a 
one year period. The results revealed an increase of 
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medication adherence during the study period of one year, 
but there were no long-term results.  
In other studies, Shon and Park provided an 
intervention,8 comprising of 12 sessions of group education 
based on self management framework. Each session was 
70-minute long. The result showed an increase in medication 
adherence. Vreeland, together with colleagues, conducted a 
study providing a 24-week psycho-education intervention 
focusing on illness management.9 The results revealed only 
an improvement in knowledge but not in medication 
adherence.  
Even though some studies showed the benefit of time 
consuming intervention,7,8 a review of the intervention for 
schizophrenia with medication adherence as an outcome 
showed the benefit of intervention with fewer sessions.10 The 
study reported that interventions were more effective to 
improve outcome even with fewer sessions (4-6 sessions) 
with focus on medication adherence and use of cognitive 
strategies.  
A representational approach focused on an individual’s 
perception has been used in several studies for individual 
with physical illness.11,12 The findings showed that the 
interventions were effective to change individuals’ behaviors 
for dealing with their health problems. However, there was 
no study of patients with mental illness.  
This research was designed with an attempt to examine 
the effect of the Illness Representation Based Education 
Program (IRBEP) on medication adherence. The intervention 
was developed based on a representational approach to 
patient education which was developed by Donovan et al.13 
The Common Sense Model (CSM)14 and Conceptual 
Change Model15-17 are the basis theories underpinning a 
representational approach to patient education.17 The CSM 
stated that cognitive illness representation influences coping 
strategies, such as medication adherence, that are used to 
overcome an illness.14 The five components of cognitive 
illness representation involve components of identity, cause, 
timeline, consequences, and controllability. The cognitive 
illness representation can be accommodated according to 
experience and information received by each individual. 
Cognitive illness representation based on misconceptions, 
gaps and confusion can be intervened and restructured 
using conceptual change model. The conceptual change 
model may help each individual successfully accommodate 
their current perceptions which includes: (1) dissatisfaction 
with the current perception because the current perceptions 
do not make sense to the individual and cannot be used to 
face the problem, (2) receiving new information which is 
intelligible and plausible, and (3) believing the new 
information to be fruitful in solving the problem.15-17  
This study examined effects of the IRBEP on medication 
adherence in patients with schizophrenia. Medication 
adherence, according to Vuckovich,18 is an individual’s 
behavior in voluntary and actively continuing taking 
medication as prescribed in order to maintain ment                    
al health. Medication adherence consists of four attributes 
which are 1) voluntary which refers to the individuals’ 
willingness in taking medication, 2) active participation which 
refers to taking responsibility regarding taking medication by 
themselves, 3) following the prescription which refers to 
individuals’ behavior following instructions regarding 
medication which is recommended by a psychiatrist, and 4) 
continuity which refers to individuals’ behavior in taking their 
medication continuously until the last dose prescribed. This 
study aimed to determine medication adherence in patients 
with schizophrenia, comparing those who did and those who 
did not the IRBEP, and to compare medication adherence 
before and after attending IRBEP. Therefore, research 
hypotheses included 1) medication adherence score in those 
attending the IRBEP was higher than those not attending, 
and 2) among those attending IRBEP, medication adherence 
score after IRBEP program was higher than that at baseline.  
  
Methods 
This study was approved by the Ethics Committee of the 
Faculty of Nursing, Prince of Songkla University. Forty 
subjects were recruited from the outpatient clinic of 
Psychiatric Hospital Banda Aceh, Indonesia. The inclusion 
criteria were as follows: Patients that (1) were diagnosed 
with schizophrenia by the psychiatrists at the Psychiatric 
Hospital Banda Aceh, (2) were aged between 18 to 60 years 
old, (3) were hospitalized at least twice due to medication 
non-adherence since diagnosis, (4) scored less than 41 on 
the Brief Psychiatric Rating Scale (BPRS), (5) were 
contactable by phone, (6) had intact communication acuity, 
(7) willingly participated in the study throughout the course of 
the study.   
Due to the reason that no previous study used the 
representational approach in patients with mental illness 
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including schizophrenia, a sample size calculation was not 
possible. Therefore, initially a minimum of 20 subjects per 
group were recruited. However, on post-hoc computation, 
the effect size was calculated, and yielded a value of 2.06. 
With a one-tailed test at a significant level of 0.01 (α = 0.01), 
an effect size of ≥ 1.40, and number of samples of 20 per 
group, the power of the test was 0.97.19 This finding was 
satisfactory and confirmed that the sample size of this study 
was adequate.  
Patients were assigned into an experiment or control 
group by using covariates adaptive randomization. The two 
controlled covariates were family support and dosage 
frequency. Family support was assistance oriented, tasked 
with helping patients to complete the course of medication, 
with three levels of low, moderate, and high. The dosage 
frequency had two levels: once per day and more than once 
per day. Therefore, there were six subgroups based on the 
combination of covariates.  
For patients in the experiment group, they participated in 
the Illness Representation Based Education Program 
(IRBEP) individually. The IRBEP consists of seven process 
components, involving (1) representation assessment in 
which the patient described his or her perception about 
schizophrenia regarding to the five dimensions of cognitive 
illness representation (identity, cause, timeline, 
consequences, and controllability) and the researcher 
identifies gaps, misconceptions, and/or confusion in the 
patient’s perception, (2) identifying and exploring the gaps, 
misconceptions and confusion about schizophrenia in which 
the researcher understands how any gaps, misconceptions 
and confusion about schizophrenia developed and evaluates 
the strength of those in patient’s behavior of medication 
adherence, (3) creating the condition for conceptual change, 
in which the patient recognizes the limitation of current 
perceptions by realizing the negative consequences of those 
perceptions, in order to overcome the schizophrenia, (4) 
introducing replacement information in which the researcher 
gives information associated with the concept of 
schizophrenia that is intelligible, plausible and fruitful in order 
to replace misconception, fill the gaps, and clarify any 
confusing issue, (5) summary in which the researcher and 
the patient summarize and discuss the benefit of the new 
perception while the patient uses it to overcome the 
schizophrenia, (6) goal setting and strategy planning in order 
to enhance medication adherence in which the patient 
decides upon goals toward taking medication then writes 
them down on the form that is provided by the researcher, 
as a strategy to enhance medication adherence, and (7) 
following up the goals and the strategies by phone allowing 
the researcher to evaluate the actions and the goals, and 
barriers.  
In the experiment group, after completing the pre-test 
data, patients were provided the first six components of the 
IRBEP. In the following week, the researcher provided the 
follow up session which was the seven-process component 
of the IRBEP. One week after that, the post-test data and 
complete patients’ monitoring form were collected. The 
monitoring form was completed in order to assess if the 
patients received any other intervention programs during 
their participation in this study. In the control group, patients 
received standard care. The pre-test and post-test (two 
weeks after pre-test) data in the control group were 
collected. Pre-test and post-test in the experiment and 
control groups were collected by a trained research assistant 
(RA) who works in a ward of the Psychiatric Hospital Banda 
Aceh and has graduated with a Bachelor of Nursing degree. 
The RA was trained to better understand the content of each 
questionnaire and to better perform data collection. The RA 
was blinded to patients regarding the intervention assigned.  
Measurements tools used in this study included the Brief 
Psychiatric Rating Scale (BPRS), the Demographic Data 
Questionnaire (DDQ), the Family Support as Assistance 
Oriented Task in Taking Medication Questionnaire 
(FSATMQ), the Cognitive Illness Representation 
Questionnaire for Schizophrenia (CIRQS) and the Behavior 
of Medication Adherence Questionnaire (BMAQ). Details of 
the instruments are follows. Firstly, the BPRS, developed by 
Overall and Gorham,20 was used to screen potential patients 
in this study. The BPRS consists of 18 items measuring 
psychiatric symptoms with a Likert-type rating scale from 1 
(not present) to 7 (extremely severe), yielding a possible 
range of 18 - 126.  
Secondly, the DDQ which was developed by the 
researcher was used to assess demographic and clinical 
characteristics. Thirdly, the FSATMQ developed by the 
researcher was used to measure the level of family support 
with a Likert-type rating scale from 1 (never) to 5 (always). 
The FSATMQ is divided into three levels with a possible 
range of 5 to 25, categorized into high level (19 - 25), 
moderate level (12 - 18) and low level (less than or equal 
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11). Fourthly, the CIRQS, modified from IPQS developed by 
Lobban, Barrowclough and Steven,21 was used to assess the 
cognitive illness representation. This information obtained 
from the CIRQS was used to ascertain the patients’ cognitive 
illness representation before and after intervention.  
Fifthly, the BMAQ was used to measure medication 
adherence with a Likert scale from 1 (never) to 4 (all the 
time) for positive statement and from 1 (all the time) to 4 
(never) for negative statement. The BMAQ was developed 
by the researcher based on the literature review on 
medication adherence reported by Cohen,22 Vrijjens et al23 
and Vuckovich.18 There were four subscales: voluntary, 
active participation, following prescription, and continuity. 
After score reversal of appropriate items, the higher score of 
BMAQ indicates higher medication adherence behavior with 
a possible range of 15 to 60.  
Validity of the study instruments (the IRBEP, goal setting 
and planning strategies form, the DDQ, the FSATMQ, the 
CIRQS and the BMAQ) were evaluated by three experts, 
including two lecturers from the Faculty of Nursing, Prince of 
Songkla University, an expertise in CSM and a psychiatric 
nurse, and one lecturer from the Faculty of Nursing, 
Indonesia University, an expertise in psychiatric nursing. The 
researcher revised the instruments by following suggestions 
from three experts. Content Validity Index (CVI) was 
calculated only for the FSATMQ, the CIRQS and the BMAQ, 
and acceptable content validity index (CVI) was found with 
value of 1.00, 0.89 and 0.80. 
Cronbach’s alpha coefficient was used to test reliability 
for FSATMQ, BMAQ, label which is one part of identity 
dimension of CIRSQ, cause dimension of CIRSQ, timeline 
dimension (chronic/acute and cycle) of CIRSQ, 
consequences dimension of CIRSQ, controllability dimension 
of CIRSQ and Kappa coefficient was used to test reliability 
of symptoms part which is one part of identity dimension of 
CIRSQ. Result showed acceptable reliability (Cronbach’s 
alpha coefficients of 0.72 - 0.87), except for chronic/acute as 
a part of the timeline dimension and consequences 
dimension (Cronbach’s alpha coefficients of 0.56 and 0.52 
respectively). Kappa coefficient for symptoms part of the 
identity dimension of CIRSQ was 0.69.  
 
Statistical analysis  
The demographic and clinical characteristics of the 
patients were analyzed by using descriptive statistics which 
consists of frequencies, percentages, mean (M) and 
standard deviation (SD). The chi-square test, Fisher’s exact 
test, Likelihood Ratio or Independent t-test were used to 
examine the differences between the experiment and control 
groups. Differences of medication adherence behaviors were 
analyzed using inferential statistics. The assumption of 
normality and homogeneity of variance were tested. The 
independent t-test statistic for between the groups and 
paired t-test statistic for within the group were used to detect 
significant differences of medication adherence. A statistical 
significance level of 0.05 was used.  
   
Results 
 
Of 40 patients, 20 in each group, they were in an age 
range of 21 – 60 years with comparable average ages 
(36.95 years n experiment group and 35.20 in control group) 
(Table 1). There were more male patients in both groups 
(65.0% in both groups). All of them were Muslim. The 
majority in both groups was single (65.0% and 50.0% in 
experiment and control groups respectively), and had senior 
high school educations (45.0% and 40.0% in experiment and 
control groups respectively). While three-quarters (75.0%) of 
patients in experiment group were currently employed, 50% 
in control group were not. Regarding monthly income, while 
the majority in control group (50.0%) had no income, those 
in experiment group had income in a wider range. Most 
patients had their family members to take care of them 
(85.0 % and 100.0% in experiment and control groups 
respectively). All differences between the two groups 
mentioned above were not statistically significant.  
Regarding clinical status, the experiment and control 
groups had comparable number of hospitalization (3.75 and 
3.62 times, respectively) and length of illness (9.77 and 8.37 
years, respectively) (Table 2). In terms of transportation, 
however, most patients in experiment group used personal 
transportation (70.0%) while those in control group used 
public (35.0%), personal (45.0%), and both public and 
person transportation (20.0%) with a statistical significance 
(P = 0.04). The majority in both groups used atypical 
antipsychotics (95.0% and 85.0%, respectively), with two-
time daily dosing (65.0% and 75.0%, respectively), and 
experiencing medication side effects (90.0% and 85.0%, 
respectively). They had comparable BPRS scores (23.80 
and 23.35 in experiment and control groups, respectively).   
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Table 1 Demographic characteristics of participants (N = 40)  
Characteristics 
Experiment 
Group 
(n = 20) 
Control  
Group 
(n = 20) 
Statistics 
Test value 
P 
Age (Year) (min-max = 21 – 60) –– M (SD) 36.95 (7.73) 35.20 (8.96) 0.66a 0.51 
Gender  
Male –– n (%) 
Female –– n (%) 
 
13 
7 
(65.00)
(35.00)
 
13 
 7 
(65.00)
(35.00)
0.00b 1.00 
Religion 
Islam –– n (%) 
Non Islam –– n (%)  
 
20 
0 
(100.00)
(00.00)
 
20 
 0 
(100.00)
(00.00)
0.00b 1.00 
Marital status 
Single –– n (%) 
Married –– n (%) 
Widower/ Widow –– n (%) 
 
13 
4 
3 
(65.00)
(20.00)
(15.00)
 
10 
 8 
 2 
(50.00)
(40.00)
(10.00)
1.95c 
 
0.37 
Educational level 
No formal education –– n (%) 
Elementary school –– n (%) 
Junior high school –– n (%) 
Senior High school –– n (%) 
University –– n (%) 
Others –– n (%) 
 
0 
2 
3 
9 
5 
1 
 (0.00)
(10.00)
(15.00)
(45.00)
(25.00)
(5.00)
 
 1 
 3 
 6 
 8 
 1 
 1 
 (5.00)
(15.00)
(30.00)
(40.00)
 (5.00)
 (5.00)
5.58c 0.35 
Occupation  
Employee –– n (%) 
No employee –– n (%) 
 
15 
5 
(75.00)
(25.00)
 
10 
10 
 (50.00)
 (50.00)
2.67b 0.10 
Monthly income (IDR) 
No income –– n (%) 
< 500,000 –– n (%) 
500,000 - 1,000.000 –– n (%) 
> 1,000,000 –– n (%) 
 
5 
6 
3 
6 
(25.00)
(30.00)
(15.00)
(30.00)
 
10 
 4 
 4 
 2 
(50.00)
(20.00)
(20.00)
(10.00)
4.34c 
 
0.23 
Number of family member in household 
>4 persons –– n (%) 
4 – 5 persons –– n (%) 
>5 persons –– n (%) 
 
3 
10 
7 
(10.00)
(5.00)
(35.00)
 
 6 
 8 
 6 
(15.00)
(15.00)
(30.00)
1.32c 0.52 
Family members take care 
No –– n (%) 
Yes –– n (%) 
 
3 
17 
(15.00)
(85.00)
 
 0 
20 
 (0.00)
(100.00)
3.24d 0.23 
Note: a = Independent t-test, b = Chi-square test, c = Likelihood Ratio, d = Fisher Exact test.  
 
Table 2 Clinical characteristics of participants (N = 40)  
Characteristics 
Experiment  
Group 
(n = 20) 
Control  
Group 
(n = 20) 
Statistics 
Test value 
P 
Number of hospitalization (min-max = 2 – 15 times) –– 
M (SD) 
5.55  (3.75) 4.85  (3.62) 0.60a 0.55 
Length of Illness –– M (SD) 
(Range = 1 years – 42 years and 8 months)  
13.57 (9.77) 11.09  (8.37) 0.86a 0.39 
Transportation 
Public –– n (%) 
Personal –– n (%) 
Public and Personal –– n (%) 
 
 6 
14 
 0 
(30.00)
(70.00)
 (0.00)
 
 7 
 9 
 4 
(35.00)
(45.00)
(20.00)
6.72c 0.04 
Experience of side effects 
No –– n (%) 
Yes –– n (%) 
 
 2 
18 
 (10.00)
(90.00)
 
 3 
17 
(15.00)
(85.00)
0.23d 
 
1.00 
 
Past experience on joining therapy programs 
No –– n (%) 
Yes –– n (%) 
 
10 
10 
(50.00)
(50.00)
 
 5 
15 
(25.00)
(75.00)
2.67b 
 
 
0.10 
 
 
Antipsychotics  
Typical –– n (%) 
Atypical –– n (%) 
 
 3 
19 
(15.00)
(95.00)
 
 8 
17 
(40.00)
(85.00)
 
3.14b 
1.11d 
 
0.08 
0.61 
Dosage Frequency (times/day) 
One time –– n (%) 
Two times –– n (%) 
Three times –– n (%) 
 
 2 
 13 
 5 
 (10.00)
 (65.00)
 (25.00)
 
 3 
15 
 2 
(15.00)
(75.00)
(10.00)
1.67c 0.43 
BPRS score (Range = 18 – 30) –– M (SD)  23.80  (3.04) 23.35  (2.83) 0.49a 0.63 
Note: a = Independent t-test, b = Chi-square test, c = Likelihood Ratio, d = Fisher Exact test, BPRS = Brief 
Psychiatric Rating Scale  
 
Result of medication adherence between groups is 
shown in table 3. Comparing the medication adherence 
between experiment group and control group, there was a 
significant difference at post-test (t = 6.53, P < 0.01) with no 
difference at pre-test (t = 0.64, P > 0.05). At post-test, the 
total mean score of medication adherence of experiment 
group was significantly higher (M = 56.65, SD = 3.28) than 
control group (M = 45.00, SD = 7.28) (P < 0.001).  
 
Table 3 Comparison of the medication adherence between 
groups using independent t-test (N = 40) 
  
Experiment 
Group 
(n = 20) 
Control 
Group 
(n = 20) 
t P 
M SD M SD 
Pre-test     
Total  45.35 8.41 43.75 7.45 0.64 0.530 
Voluntary  12.75 3.24 12.35 2.96 0.41 0.686 
Active participation 8.35 2.66 7.35 2.13 1.31 0.198 
Following prescription 12.45 2.48 12.55 1.82 -0.15 0.885 
Continuously 11.80 2.69 11.50 3.20 0.32 0.750 
Post-test      
Total 56.65 3.28 45.00 7.28 6.53 < 0.001 
Voluntary  15.40 .99 12.60 2.98 3.99 < 0.001 
Active participation 10.85 1.14 7.55 2.24 5.89 < 0.001 
Following prescription 15.05 1.09 12.75 1.77 4.93 < 0.001 
Continuously 15.35 1.18 12.10 3.02 4.48 < 0.001 
 
The result of medication adherence within group is 
shown in table 4. The medication adherence of patients in 
the experiment group had significant difference between Pre-
test and Post-test (t = -6.09, P < 0.01). The total mean score 
of medication of the patients in the experiment group at post- 
  
Table 4 Comparison of the medication adherence within group 
using paired t-test (N = 40) 
 
Pre-test Post-test 
t P 
M SD M SD 
Experiment Group (n = 20)       
Total  45.35 8.41 56.65 3.28 -6.09 < 0.001 
Voluntary  12.75 3.24 15.40 .99 -3.54 0.002 
Active participation 8.35 2.66 10.85 1.14 -4.32 < 0.001 
Following prescription 12.45 2.48 15.05 1.09 -4.54 < 0.001 
Continuity 11.80 2.69 15.35 1.18 -5.91 < 0.001 
Control Group (n = 20)       
Total 43.75 7.45 45.00 7.28 -1.23 0.236 
Voluntary  12.35 2.96 12.60 2.98 -1.16 0.262 
Active participation 7.35 2.13 7.55 2.24 -0.61 0.551 
Following prescription 12.55 1.82 12.75 1.77 -0.75 0.464 
Continuity 11.50 3.20 12.10 3.02 -0.99 0.337 
 
-test was significant higher (M = 56.65, SD = 3.28) than pre-
test (M = 45.35, SD = 8.41). The medication adherence of 
the patients in the control group was not significantly 
different between pre-test and post-test (t = -1.23, P > .05), 
although the total means score of the medication adherence 
in the post-test (M = 45.00, SD = 7.28) was higher than pre-
test (M = 43.75, SD = 7.45).  
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Discussions and Conclusion 
   
In this clinical study to determine effect of IRBEP 
program to improve medication adherence among 
Indonesian schizophrenic patients, the patients in the 
experiment group had significantly higher medication 
adherence than the patients in the control group (t = 6.53, P 
< 0.01). The patients in the experimental group had 
significantly higher medication adherence after attending the 
IRBEP than before attending IRBEP (t = -6.09, P < 0.01).  
Findings supported that IRBEP improved medication 
adherence in schizophrenia patients. Patients’ perceptions 
towards schizophrenia influenced their behavior in taking 
prescribed medication. Patients accommodated their current 
perceptions which were misconceptions, gaps, and/or 
confusion to new perceptions after the IRBEP. Awareness of 
negative consequences and limitations of current perceptions 
were raised. A new perception was formed after receiving 
new information that was intelligible, plausible, and fruitful.16 
In this study, in order to achieve successful outcomes, the 
researcher had educated patients by providing new 
information about concepts of schizophrenia, which was 
relevant to patients’ past experience and ability to solve the 
schizophrenia by means of a crucial factor, namely 
medication adherence. Therefore, the patients would 
accommodate their current perceptions to new perceptions.  
Enhancing medication adherence among the patients in 
the experimental group was contributed by the perceptions’ 
of the patients about cause, timeline and controllability of 
schizophrenia. Firstly, after the patients in the experimental 
group learned that chemical imbalance in the brain causes 
schizophrenia, adherence improved to a higher than before 
when they more than likely perceived that Allah SWT 
(spiritual belief) as the cause of their schizophrenia. For 
example, at the beginning, patients believed that the cause 
of the illness was a punishment from Allah SWT, for their 
past bad behavior, or as a test from Allah SWT to draw them 
closer to Allah SWT and doing what Allah SWT orders to 
Muslims following the holy Al-Qur’an. Therefore, after their 
mental health improved, patients would not continue to take 
medication, but rather pray and practice good faith as taught 
in their religion. Patients with mental illness who believed 
God was the cause of the mental illness perceived that using 
spiritual solutions would be more useful than using 
medication.24 The reason that patients in the experiment 
group were more likely to adhere to medication after the 
IRBEP was because they believed that medication has a 
role balancing the chemicals in the brain.  
Secondly, perception of the timeline of schizophrenia, 
most of the patients in the experimental group after 
intervention perceived schizophrenia as a chronic and cyclic 
illness rather than as an acute illness. Adherence to long 
term medication was higher in this group. Our findings were 
supported by Aflakseir,25 who also found that medication 
adherence was significantly influenced by the perception of 
illness as a chronic illness.  
Thirdly, the positive perception of medication 
controllability to overcome schizophrenia was significantly 
different between the two groups, both before and after the 
IRBEP. According to Lobban and colleagues26 patients with 
schizophrenia were more likely to adhere to their medication 
if they believed that the treatment would be able to control 
their symptoms. It is also supported by several studies,4, 25, 27 
that the belief of medication efficacy to control unwanted 
symptoms has been associated with medication adherence. 
Developing goals setting, creating strategies to achieve 
those goals and close monitoring during follow up, played a 
significant role in improving medication adherence in our 
study. Specifically setting goals and planning strategies 
provided by the individual is needed to set the individual’s 
behavior to overcome the health problem.14 In our study, 
subjects had the opportunity to set goals which aimed to 
enhance medication adherence and chose the strategies 
appropriate to achieve their goals. From a review of literature 
of intervention for patient with schizophrenia, focusing on 
medication adherence as a primary goal, suggested that 
intervention had a successful effect on enhancing medication 
adherence.10 During the follow up, if the subjects 
experienced any barrier while applying the strategies, the 
researcher would discuss and suggest a way to deal with. 
Using a follow up in the interventions for schizophrenic 
patients has shown to be effective in enhancing medication 
adherence.10 
This quasi-experimental study provides the effectiveness 
of the intervention on medication adherence in patients with 
schizophrenia. The strength of this study was the 
intervention of the IRBEP that focused on individual’s 
representation of illness in which the representation was 
documented to influence medication adherence. The IRBEP 
replaced the individual’s representation that was 
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misconception, gaps or confusion. The process of the IRBEP 
focused on representation that is unique for each individual. 
The limitation of this study was the measurement used. The 
Behavior of Medication Adherence Questionnaire (BMAQ) 
and the Cognitive Illness Representation Questionnaire for 
Schizophrenia (CIRQS) were developed and used for the 
first time. Further studies are needed to support the findings.  
 
Conclusion  
An improvement of medication adherence among 
schizophrenia patients undergoing the IRBEP is evident in 
this study. Medication adherence is influenced by an 
individual’s cognitive illness representation, especially the 
representation of the cause, timeline and controllability of 
schizophrenia. It is thus important for health care providers 
to know how an individual’s thoughts relate to his/her health 
and illness behaviors. Furthermore, using the IRBEP in 
these patients as a discharge planning tool will significantly 
augment cooperation and improve patients’ outcomes.   
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